{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:03:04Z","timestamp":1780538584775,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2002,5]]},"DOI":"10.3816\/cbc.2002.s.002","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T21:03:50Z","timestamp":1221167030000},"page":"S8-S11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"S1","title":["Overview: Gemcitabine as Single-Agent Therapy for Advanced Breast Cancers"],"prefix":"10.3816","volume":"3","author":[{"given":"Debu","family":"Tripathy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2002.s.002_bib1","first-page":"33","article-title":"Cancer statistics, 2001","volume":"49","author":"Greenlee","year":"2001","journal-title":"CA Cancer J Clin"},{"key":"10.3816\/CBC.2002.s.002_bib2","first-page":"33","article-title":"Global cancer statistics","volume":"49","author":"Parkin","year":"1999","journal-title":"CA Cancer J Clin"},{"key":"10.3816\/CBC.2002.s.002_bib3","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2002.s.002_bib4","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","article-title":"Polychemotherapy for early breast cancer: an overview of the randomised trials","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.3816\/CBC.2002.s.002_bib5","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"10.3816\/CBC.2002.s.002_bib6","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.1998.16.10.3439","article-title":"Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women","volume":"16","author":"Fossati","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2002.s.002_bib7","first-page":"101","article-title":"Management of metastatic breast cancer: reasons for optimism","volume":"2","author":"Munster","year":"1999","journal-title":"Oncology Special Edition"},{"key":"10.3816\/CBC.2002.s.002_bib8","first-page":"6110","article-title":"Action of 2\u2032,2\u2032-difluorodeoxycytidine on DNA synthesis","volume":"51","author":"Huang","year":"1991","journal-title":"Cancer Res"},{"key":"10.3816\/CBC.2002.s.002_bib9","first-page":"29","article-title":"Cellular elimination of 2\u2032,2\u2032-difluorodeoxycytidine 5\u2032-triphosphate (dFdCTP)","author":"Heinemann","year":"1988","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.3816\/CBC.2002.s.002_bib10","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/0006-2952(92)90077-V","article-title":"Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2\u2032,2\u2032-difluorodeoxycytidine","volume":"44","author":"Xu","year":"1992","journal-title":"Biochem Pharmacol"},{"key":"10.3816\/CBC.2002.s.002_bib11","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/07328318908054215","article-title":"2\u2032,2\u2032-difluorodeoxycytidine metabolism and mechanism of action in human leukaemia cells","volume":"8","author":"Plunkett","year":"1989","journal-title":"Nucleosides Nucleotides"},{"key":"10.3816\/CBC.2002.s.002_bib12","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1021\/jo00246a002","article-title":"Synthesis of 2-deoxy-2\u2032,2\u2032-difluoro-Dribose and 2-deoxy-2\u2032,2\u2032-difluoro-D-ribofuranosyl nucleosides","volume":"53","author":"Hertel","year":"1988","journal-title":"J Org Chem"},{"key":"10.3816\/CBC.2002.s.002_bib13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","article-title":"A phase I clinical, plasma, and cellular pharmacology study of gemcitabine","volume":"9","author":"Abbruzzese","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2002.s.002_bib14","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2002.s.002_bib15","series-title":"Gemzar (gemcitabine HCL) [package insert]","year":"1998"},{"key":"10.3816\/CBC.2002.s.002_bib16","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/oxfordjournals.annonc.a058808","article-title":"Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group","volume":"5","author":"Cormier","year":"1994","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2002.s.002_bib17","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/jnci\/86.20.1530","article-title":"Phase II study of gemcitabine (2\u2032,2\u2032-difluorodeoxycytidine) in previously treated ovarian cancer patients","volume":"86","author":"Lund","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2002.s.002_bib18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.1996.0284","article-title":"Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel","volume":"63","author":"Shapiro","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.3816\/CBC.2002.s.002_bib19","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1200\/JCO.1995.13.11.2731","article-title":"Advanced breast cancer: a phase II trial with gemcitabine","volume":"13","author":"Carmichael","year":"1995","journal-title":"J Clin Oncol"},{"issue":"suppl 8","key":"10.3816\/CBC.2002.s.002_bib20","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/S0959-8049(97)85244-6","article-title":"Phase II study of gemcitabine in patients with metastatic breast cancer","volume":"33","author":"Blackstein","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2002.s.002_bib21","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1054\/brst.2000.0170","article-title":"Single agent gemcitabine as second- and third-line treatment in metastatic breast cancer","volume":"9","author":"Brodowicz","year":"2000","journal-title":"The Breast"},{"key":"10.3816\/CBC.2002.s.002_bib22","first-page":"145a","article-title":"Gemcitabine response in advanced breast cancer in relation to immunohistochemical factors","volume":"19","author":"Gerson","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2002.s.002_bib23","first-page":"516","article-title":"Gemcitabine (G) in pretreated breast cancer (BC)","volume":"20","author":"Valerio","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2002.s.002_bib24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000058524","article-title":"Single-agent gemcitabine is active in previously treated metastatic breast cancer","volume":"60","author":"Spielmann","year":"2001","journal-title":"Oncology"},{"key":"10.3816\/CBC.2002.s.002_bib25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00001813-199902000-00003","article-title":"Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer","volume":"10","author":"Possinger","year":"1999","journal-title":"Anticancer Drugs"},{"key":"10.3816\/CBC.2002.s.002_bib26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/00001813-199908000-00001","article-title":"Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer","volume":"10","author":"Schmid","year":"1999","journal-title":"Anticancer Drugs"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911702798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911702798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:07:27Z","timestamp":1761512847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911702798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":26,"alternative-id":["S1526820911702798"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2002.s.002","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2002,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overview: Gemcitabine as Single-Agent Therapy for Advanced Breast Cancers","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2002.s.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}